TP53 and ovarian cancer: More broadly, Dr. Elizabeth Swisher of the University of Washington noted that wild-type TP53 was virtually absent in ovarian cancers with BRCA mutations but relatively common, ~30%, in BRCA wild-type tumors (Personal Communication).